A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.

@article{Seo2010ASN,
  title={A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.},
  author={Ji-Heui Seo and Lisa J. Wood and Anupriya Agarwal and T. O'hare and Collin R. Elsea and Ian J. Griswold and Michael W N Deininger and Akira Imamoto and Brian J. Druker},
  journal={Cancer research},
  year={2010},
  volume={70 18},
  pages={
          7325-35
        }
}
CRKL (CRK-like) is an adapter protein predominantly phosphorylated in cells that express the tyrosine kinase p210(BCR-ABL), the fusion product of a (9;22) chromosomal translocation causative for chronic myeloid leukemia. It has been unclear, however, whether CRKL plays a functional role in p210(BCR-ABL) transformation. Here, we show that CRKL is required for p210(BCR-ABL) to support interleukin-3-independent growth of myeloid progenitor cells and long-term outgrowth of B-lymphoid cells from… 

Figures from this paper

Characterization of Signal Transduction Abnormalities Revealed Spleen Tyrosine Kinase as a Therapeutic Target in High-risk Precursor B Cell Acute Lymphoblastic Leukemia
TLDR
This study demonstrated that pre-B cell receptor-independent spleen tyrosine kinase (SYK) activity was required for the survival and proliferation of a p53 -/Prkdc SCID/SCID mouse model of B-ALL, and identified that fostamediated inhibition of SYK was predictive of its anti-leukemic activity, and was distinct from the cellular actions of other small molecule inhibitors of key nodal signaling pathways.
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL
TLDR
By degrading the native and T315I-mutant BCR-ABL, the chimeric ubiquitin ligase SH2-U-box may serve as a potential therapy for both imatinib-sensitive and resistant CML.
Crk and CrkL are required for cell transformation by v‐fos and v‐ras
TLDR
It is suggested that both Crk and CrkL are required for the acquisition of cellular transformation by v‐fos, whereas Crk plays a more prominent role thanCrkL in v‐ras‐induced transformation.
JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia.
TLDR
Recent evidence is presented showing that CML stem cells do not depend on BCR-ABL1 kinase activity but require the continuous support of the hematopoietic niche and its distinct cytokine environment and it is suggested that it has the potential to resolve the dispute.
Combination of Bortezomib and Mitotic Inhibitors Down-Modulate Bcr-Abl and Efficiently Eliminates Tyrosine-Kinase Inhibitor Sensitive and Resistant Bcr-Abl-Positive Leukemic Cells
TLDR
It is shown that the combined regimens of bortezomib with mitotic inhibitors, such as the microtubule-stabilizing agent Paclitaxel and the PLK1 inhibitor BI2536, efficiently kill TKIs-resistant and -sensitive Bcr-Abl-positive leukemic cells.
Domain organization differences explain Bcr-Abl’s preference for CrkL over CrkII
TLDR
The data show that CrkL forms a constitutive complex with Abl thus explaining the strong preference of Bcr-Abl for Crkl, and highlights how the structural organization of the modular domains in adaptor proteins can control signaling outcome.
Models of crk adaptor proteins in cancer.
TLDR
The Crk family of adaptor proteins, originally discovered as the oncogene fusion product, v-Crk, of the CT10 chicken retrovirus, lacks catalytic activity but engages with multiple signaling pathways through their SH2 and SH3 domains, acting as adaptors in diverse signaling pathways and cellular processes.
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
TLDR
This study reports the development of a peptide inhibitor, PRM-3, targeting the interaction between CRK-II and ABL kinase, and provides a promising alternative approach to overcome the drug resistance of ABL Kinase.
Natural course and biology of CML
TLDR
The presence of BCR-ABL1 can explain virtually all the cellular features of the leukaemia (enhanced cell growth, inhibition of apoptosis, altered cell adhesion, growth factor independence, impaired genomic surveillance and differentiation).
...
...

References

SHOWING 1-10 OF 68 REFERENCES
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
TLDR
The data suggest that CRKL function may still be required for BCR-ABL function through an indirect interaction, and suggests that a direct interaction is not required forCRKL to become tyrosine phosphorylated by BCR -ABL.
Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice.
TLDR
Overexpression of Crkl was associated with increased incidence of tumor formation, and Rap1 was activated in a metastatic mammary carcinoma, which provides direct evidence that Crkl plays a role in tumor development and is important in the leukemogenesis caused by Bcr/Abl.
Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia.
TLDR
It is shown that in peripheral blood cells a direct correlation exists between the presence of BCR/ABL and the phosphorylation status of CRKL, which strongly suggests thatCRKL is a biologically significant substrate for BCR or ABL and is likely to play a major role in the development of Ph+ leukemia.
Structural Requirements for Function of the Crkl Adapter Protein in Fibroblasts and Hematopoietic Cells
TLDR
It is found that overexpression of Crkl confers a signal leading to increased adhesion to fibronectin and implicate Crkl in cellular adhesion and demonstrate that Y207 functions as a negative regulatory site.
In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome.
TLDR
A retroviral gene-transfer system is used to express P210 in mouse bone marrow cells to evaluate the sequential and perhaps synergistic involvement of the P210 gene and other oncogenes as models for the progressive changes observed in human chronic myelogenous leukemia.
BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl
TLDR
Western blot analysis of −/− and +/+ lymphomas showed that the related Crk protein was tyrosine phosphorylated and could be found complexed with Bcr–Abl P190, indicating that possible therapeutic approaches that target Crkl may be complicated by the presence of pathways that compensate for lack of Crkl function.
Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site
TLDR
Findings suggest that complex formation with cellular targets is not modulated by CRKL tyrosine-phosphorylation, and indicate that Y207 inCRKL represents the major in vivo phosphorylation site.
Identification of CRKL as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells.
TLDR
The results suggest that pp39 CRKL in CML neutrophils may be stably tyrosine-phosphorylated by the BCR/ABL kinase at an early stage of myeloid differentiation when the ABL kinase is active.
Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.
  • G. Daley, D. Baltimore
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1988
TLDR
It is established that P210bcr/abl can transform hematopoietic cell types to tumorigenicity and for autocrine production of interleukin 3 by factor-independent cell lines was found.
...
...